A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases
Clinical trial NCT06218888 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06218888
- Sponsor
- Fujian Cancer Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-01
- Primary completion
- 2025-12-01
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.